MENU

KURA Stock Kura Oncology (KURA, $21.49) Moving Average Convergence Divergence (MACD) Histogram turned negative on May 28, 2024

A.I.dvisor
at Tickeron.com
05/29/24
Loading...
KURA - Kura Oncology
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $21.49
Daily change: +$0.32 (+1.51%)
Daily volume: 436.4K
Capitalization: $1.6B
Industry: Biotechnology
This is a Bearish indicator signaling KURA's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 36 similar cases where KURA's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

Momentum Indicator for KURA turns negative, indicating new downward trend

KURA saw its Momentum Indicator move below the 0 level on November 14, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned negative. In of the 74 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

KURA broke above its upper Bollinger Band on November 12, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for KURA entered a downward trend on November 11, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KURA's RSI Indicator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where KURA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for KURA just turned positive on November 04, 2024. Looking at past instances where KURA's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.026) is normal, around the industry mean (14.905). P/E Ratio (0.000) is within average values for comparable stocks, (98.894). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.944). KURA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (217.940).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
KURA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of biopharmaceutical services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12730 High Bluff Drive
Phone
+1 858 500-8800
Employees
142
Web
https://www.kuraoncology.com